TransCode Therapeutics Announces $8 Million Funding Initiative
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has taken a significant step forward in its mission to advance cancer treatment through an announcement of a private placement. The company, known for its dedication to developing RNA therapeutics, has recently entered into a securities purchase agreement with select institutional investors, anticipating approximately $8 million in gross cash proceeds. This funding will be crucial for enhancing its operations and supporting its overall corporate activities.
Details of the Private Placement
The private placement will involve the issuance of 21,220,160 shares of common stock, which may also be accompanied by pre-funded warrants. Additionally, investors will receive Series C and Series D warrants, each enabling the purchase of the same number of shares of common stock. The pricing structure for this offering is designed to align with current market conditions under Nasdaq regulations. Specifically, the purchase price stands at $0.377 for each unit, which encompasses one share and the related warrants.
Future Implications of the Funding
The net proceeds from this private placement are earmarked for general corporate purposes and working capital, providing TransCode with the essential resources to further its clinical pipeline. The Series C and D warrants will be exercisable upon stockholder approval, with a substantial term of five years for Series C and two and a half years for Series D. This strategic financial maneuver sets the stage for future growth and innovation.
Expectations Regarding Closing
TransCode anticipates that the transaction will close on or around a specific date, pending customary closing conditions. The Benchmark Company, LLC has been appointed as the exclusive placement agent for this offering, highlighting its importance in the strategic financial direction of the company.
About TransCode Therapeutics
TransCode is a clinical-stage oncology company focused on battling metastatic disease through the innovative application of RNA therapeutics. The company’s flagship therapeutic candidate, TTX-MC138, specifically targets metastatic tumors that overexpress microRNA-10b, an established biomarker linked to cancer spread. Furthermore, TransCode is actively developing an array of novel RNA therapeutic candidates, aiming to streamline RNA delivery mechanisms and overcome inherent challenges within the field of cancer treatment.
Commitment to Innovation
The versatility and potential of RNA therapeutics present an exciting frontier in oncology, and TransCode’s commitment to innovation is underscored by its proprietary TTX nanoparticle platform. This platform enhances the precision and efficacy of RNA-based therapies, promising improved outcomes for cancer patients.
Contact Information
For any inquiries, interested parties can reach out to:
TransCode Therapeutics, Inc.
Tania Montgomery-Hammon, VP of Business Development
tania.montgomery@transcodetherapeutics.com
Frequently Asked Questions
What is TransCode Therapeutics focusing on?
TransCode Therapeutics is focused on developing RNA therapeutics aimed at effectively treating cancer, particularly metastatic disease.
How much funding did TransCode Therapeutics announce?
The company announced a private placement expected to generate approximately $8 million in funding.
What will the funding be used for?
The funds will primarily support general corporate purposes and working capital for the company's ongoing projects.
When is the anticipated closing for the private placement?
The closing is expected to occur on or around a specified date, subject to customary closing conditions.
Who is the placement agent for this offering?
The Benchmark Company, LLC is acting as the exclusive placement agent for the private placement.
